

CERTIFICATE

Survey of 15 May 2026

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis - Rivaroxaban (503):

Validity 12 months:

Rivaroxaban

(R) analysis is subject to the RiliBÄK

Customer:
10012430
MUDr. Martin Spacek, PhD.
Vseobecná fakultní nemocnice v Praze
Centrální hematologické laboratoře ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 25 June 2026



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 15 May 2026

You have participated in the External Quality Assessment with the following analysis

Haemostasis - Rivaroxaban (503):

Rivaroxaban

(R) analysis is subject to the RiliBÄK

Customer:
10012430
MUDr. Martin Spacek, PhD.
Vseobecná fakultní nemocnice v Praze
Centrální hematologické laboratoře ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 25 June 2026



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)